Literature DB >> 17555910

Neck management in medullary thyroid carcinoma.

I M Oskam1, F Hoebers, A J M Balm, F van Coevorden, E M Bais, A M Hart, M W M van den Brekel.   

Abstract

AIMS: The aims of this study were to retrospectively evaluate incidence and patterns of lymph node metastases, surgical treatment and prognostic factors of medullary thyroid carcinoma.
METHODS: Out of a group of 70 MTC patients data of 67 patients were collected. Sixty-two of these patients underwent surgery. Apart from thyroidectomy, 16 patients underwent a bilateral neck dissection, 21 a unilateral neck dissection and 29 a paratracheal dissection or node-picking operation. Thirty-six patients were irradiated, of which 31 postoperatively and five with palliative intent.
RESULTS: Lymph node metastases were found in 91% of the ipsilateral neck dissection specimens, 91% of the paratracheal dissections and 63% of the contralateral dissections. Of the 12 elective neck dissections, 5 were tumor positive. Level VI was positive in 91% of the cases where a dissection was done, whereas preoperatively only 16% were scored tumor positive. During follow-up 22 of the 67 patients developed one or more locoregional recurrences (in total 28 recurrences). The most important factors that were correlated with a worse prognosis of survival were late stage of disease (stage III and IV) (p=0.0014), high number of positive lymph nodes (p=0.0023) and incomplete surgical resection (p=0.0002).
CONCLUSIONS: The high rate of locoregional recurrences in this study are a strong argument for a more aggressive approach to the primary and neck. A routine central and ipsilateral selective neck dissection of levels II-V should be considered in all MTC patients based on the high incidence of metastases and the relative low morbidity of a unilateral neck dissection. Patients referred after thyroidectomy alone with elevated (stimulated) calcitonin levels should be re-operated, performing an elective or therapeutic central and unilateral neck dissection.

Entities:  

Mesh:

Year:  2007        PMID: 17555910     DOI: 10.1016/j.ejso.2007.03.020

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  6 in total

1.  Adjuvant external beam radiation for medullary thyroid carcinoma.

Authors:  Steve R Martinez; Shannon H Beal; Allen Chen; Steven L Chen; Philip D Schneider
Journal:  J Surg Oncol       Date:  2010-08-01       Impact factor: 3.454

2.  Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?

Authors:  D Taïeb; S Giusiano; F Sebag; M Marcy; C de Micco; F F Palazzo; N J Dusetti; J L Iovanna; J F Henry; S Garcia; Colette Taranger-Charpin
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

3.  Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.

Authors:  P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill
Journal:  Ir J Med Sci       Date:  2016-04-15       Impact factor: 1.568

4.  Medullary thyroid carcinoma: The third most common thyroid cancer reviewed.

Authors:  Michael Stamatakos; Panoraia Paraskeva; Charikleia Stefanaki; Paraskevas Katsaronis; Andreas Lazaris; Konstantinos Safioleas; Konstantinos Kontzoglou
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

5.  (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.

Authors:  Aurélien Archier; Céline Heimburger; Carole Guerin; Isabelle Morange; Fausto F Palazzo; Jean-François Henry; Olivier Schneegans; Olivier Mundler; Ahmad Esmaeel Abdullah; Frédéric Sebag; Alessio Imperiale; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-24       Impact factor: 9.236

6.  Diagnosis and treatment of a neck node swelling suspicious for a malignancy: an algorithmic approach.

Authors:  A J M Balm; M L F van Velthuysen; F J P Hoebers; W V Vogel; M W M van den Brekel
Journal:  Int J Surg Oncol       Date:  2010-05-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.